Croma-Pharma Presents juvenus, a New Polynucleotide Based Injectable for Skin Hydration and Tissue Elasticity Restoration
13.9.2021 16:00:00 EEST | Business Wire | Press release
Croma-Pharma (Croma) today announced the addition of juvenus to its product portfolio. It is an injectable, elastic, colourless and reabsorbable gel, based on polymerized polynucleotides (PDRN)1,2 of natural origin, which hydrates the skin and restores tissue elasticity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210913005466/en/
Croma-Pharma Presents juvenus, a New Polynucleotide Based Injectable for Skin Hydration and Tissue Elasticity Restoration (Photo: Business Wire)
juvenus is produced by a European certified manufacturer and distributed by Croma. In a first phase Croma will market the product within its network of affiliated sales companies (AT, FR, DE, NL, PL, PT, RO, ES, CH, UK, IT), followed by other European markets via independent distribution partners.3
Innovative mode of action to fight signs of skin aging
Thanks to its biochemical properties, juvenus improves skin elasticity and is effective against various signs of aging, such as wrinkles, loss of skin firmness or skin tone. The elastic and injectable gel is based on polymerized polynucleotides (PDRN), showing several positive effects on the skin:
- Antioxidative effect: The enzyme-related degradation of polynucleotide molecules can lead to an amplification of protective activities against free radicals. 4
- Moisturization: The hydrophilic and polyanionic structure enables PDRN to bind water molecules, resulting in an intensive moisturization of the tissue.
- Creation of an optimal environment for fibroblast growth: Extensive moisturization and the antioxidative activity contribute to the creation of an optimal physiological environment for the growth of the fibroblasts favoring the restoration of the tissue elasticity.5
Two concentrations for different types of skin blemishes
juvenus is available in two concentrations and suitable for all skin types and age groups:
- juvenus 2%, medium: slightly deeper wrinkles, such as superficial perioral wrinkles, cheek wrinkles, medium scars
- juvenus 2,5%, strong: medium-deep wrinkles and larger areas of the body, such as neck, back of the hands, abdomen, cleavage, thighs and glutes, nasogenien wrinkles, deep/large scars
Broad range of indications for facial and body treatments with a proven safety profile
The application range of juvenus is extensive and stretches from the treatment of slightly deeper facial wrinkles to the treatment of larger areas of the body.
juvenus shows a proven safety profile due to the PDRN extraction and purification at high temperature – a procedure that allows to recover an over 95% pure active substance with inactivated proteins and peptides. The latter guarantees the safety of the product and the lack of immunological side effects.
"Croma always strives to bring exceptional products to the market that meet the growing demands of our customers. With juvenus, we can offer a new and safe injectable with an innovative mode of action that targets the signs of skin aging," comments Managing Director Andreas Prinz.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high quality skincare technologies in its core strategic markets.
The medical practitioner confirms having informed the patient of a likely risk associated with the use of the medical device in line with its intended use. For risks and adverse events associated with the use of the product consult the instructions of use.
1 Müller Esterl, Biochemie. 1. Auflage 2004, Elsevier
2 Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L and Altavilla D (2017) Pharmacological Activity and Clinical Use of PDRN. Front. Pharmacol. 8:224. doi: 10.3389/fphar.2017.00224
3 available with CE 0373
4 Cavallini M, Papagni M. Long chain polynucleotides gel and skin biorevitalization. Int J Plast Dermatol 2007; 3: 27-32.
5 Pak CS, Lee J, Lee H, et al. A phase III, randomized, double-blind, matched-pairs, active-controlled clinical trial and preclinical animal study to compare the durability, efficacy and safety between polynucleotide filler and hyaluronic acid filler in the correction of crow’s feet: a new concept of regenerative filler. J Korean Med Sci 2014: 29: 201– 209.
PRJ0821
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005466/en/
Contact information
CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Tel.: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at
CROMA-PHARMA GmbH
Simone Turek
External Communications Manager
Tel.: +43 676 846868 654
Mail: simone.turek@croma.at
Web: www.croma.at
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Strengthens Argentina Presence with Fidem Partners29.9.2026 16:30:00 EEST | Press release
Andersen Global expands its tax and transaction capabilities in Argentina through a Collaboration Agreement with Fidem Partners, strengthening its presence and service offerings in the market. Established in 2011, Fidem Partners advises businesses on tax and compliance, M&A, and business process outsourcing. The firm serves companies across the energy, technology, financial services, agribusiness, and consumer goods sectors with deep experience serving subsidiaries of multinational companies in Argentina. Its multidisciplinary team draws on experience from leading professional services firms and business environments to provide practical guidance throughout the key stages of the business lifecycle. "Most of our work is with subsidiaries of multinational companies operating in Argentina, where the regulatory environment demands judgment, not just compliance," said Darío H. Díaz, managing partner of Fidem Partners. "Collaborating with Andersen Global gives our clients access to a global
CEO Pay Tops $18 Million as Turnover Drives Six-Year High in Sign-On Bonuses, According to Diligent29.9.2026 16:00:00 EEST | Press release
Median granted CEO pay at S&P 500 companies rose by more than 8% in 2025 to reach $18.2 million, while cash sign-on bonuses for incoming CEOs hit a six-year high, according to the Executive Compensation in 2026 report from Diligent Market Intelligence. The findings point to a more consequential compensation environment for boards: leadership talent is in shorter supply, CEO transitions are costly, and investors continue to scrutinize how pay decisions connect to performance and long-term value. The Russell 3000 also saw remuneration packages grow larger, with median granted CEO pay climbing over 2% to $7.4 million. “This level of growth has been fueled by performance-based equity and stock awards while both indices have been delivering strong total shareholder returns,” said Josh Black, Editor-in-Chief of Diligent Market Intelligence. “Boards are also increasingly viewing CEOs as a scarce global talent pool.” CEO turnover drives higher transition costs Cash sign-on bonuses for new S&P
Momentum Grows for Miro MCP as Users Embrace the Canvas for AI Collaboration29.9.2026 16:00:00 EEST | Press release
Miro®, the collaboration and context layer for the AI era, has reported more than 16 million calls to its MCP server since its launch in February 2026, with usage more than doubling since May. In September alone, MCP calls are on track to reach 6 million*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929837812/en/ Miro's MCP server is a Model Context Protocol integration letting AI tools connect to Miro boards—creating diagrams, tables, and canvas content, and reading existing board data programmatically. Teams increasingly rely on AI to accelerate work—from discovery and planning to design and code. Yet most AI interactions happen in chat windows or static outputs that exist separately from the team's actual workspace. Miro's MCP server changes this by giving users a way to make the output from their AI tools visual, immediately editable, and accessible to the whole team on a shared canvas. Miro user data shows Claude
I-SEC Optimizes Airport Security Workforce Planning with Gurobi and Syntro29.9.2026 16:00:00 EEST | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, and its partner Syntro, a provider of workforce scheduling solutions, are helping organizations like I-SEC, an international provider of airport security services, make better operational decisions in increasingly complex and highly regulated operating environments. As organizations face growing pressure to balance labor costs, regulatory requirements, service levels, and employee needs, many are turning to mathematical optimization to improve operational decision making. Airport security workforce planning is particularly complex, requiring organizations to align staffing levels with changing passenger volumes while adhering to strict regulations, accounting for required breaks and certifications, and ensuring coverage across multiple locations and checkpoints. Working with Syntro, I-SEC implemented a shift generator that leverages Gurobi’s solver. Rather than assigning employees directly to schedules, the solut
NTT DATA Launches ‘Intact, intelligent action.’ to Protect Fragile Places and Advance Sustainability Commitments29.9.2026 16:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced “Intact, intelligent action.” This global initiative is designed to help people and organizations translate sustainability commitments into meaningful action. The effort combines awareness, technology and stewardship in support of some of the world’s most treasured yet fragile places. Antarctica will be the first chapter. From November 25 to December 2, 2026, a dozen NTT DATA employees will join polar explorer Robert Swan and his 2041 Leadership on the Edge expedition aboard the Magellan Explorer. With the Antarctic Peninsula and nearby islands as their classroom, the NTT DATA team and more than 60 other business and community leaders will explore leadership under pressure, climate policy, sustainability and innovation with a focus on putting commitments into action. NTT DATA began working with Swan in 2022 and named him as the company’s Sustainability Ambassador in 2025. The expedition marks a 4
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom